Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3790-3799

  McGuffie, E M ^a   Pacheco, D ^a   Carbone, G M R ^a   Catapano, C V ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PURINE; PYRIMIDINE; TRIPLE HELIX FORMING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL LINE; ONCOGENE C MYC; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; TRIPLE HELIX;

ANTIGENS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL NUCLEUS; CONTRAST MEDIA; DIMETHYL SULFOXIDE; DNA; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXONS; FLUORESCEIN; HL-60 CELLS; HUMANS; LEUKEMIA; LYMPHOMA; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-MYC; RNA; S PHASE; SOLVENTS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034660876     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. c-Myc target genes involved in cell growth, apoptosis, and metabolism
2. Mysterious liaisons: The relationship between c-Myc and the cell cycle
3. Control of c-myc regulation in normal and neoplastic cells
4. MYC oncogenes and human neoplastic disease
5. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights
6. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA
7. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation
8. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells
9. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes
10. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice
11. Phosphorothioated antisense c-myc oligonucleotide inhibits the growth of human colon carcinoma cells
12. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer
13. c-myc antisense oligonucleotides inhibit the colony-forming capacity of Colo 320 colonic carcinoma cells
14. Triplex DNA: Fundamentals, advances, and potential applications for gene therapy
15. Triple helix formation and the antigene strategy for sequence-specific control of gene expression
16. Prospects for the therapeutic use of antigene oligonucleotides
17. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro
18. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter
19. Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells
20. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels
21. Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex
22. Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene
23. Phosphorothioate oligonucleotide-directed triple helix formation
24. Inhibition of gene expression by triple helix formation in hepatoma cells
25. Selective inhibition of monocyte chemoattractant protein-I gene expression in human embryonal kidney cells by specific triple helix-forming oligonucleotides
26. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
27. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26
28. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas
29. MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination
30. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1
31. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells
32. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
33. Nucleic acid therapeutics: State of the art and future prospects
34. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins
35. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line
36. Activation and somatic mutation of the translocated c-myc gene in Burkitt lymphoma cells
37. Synthetic oligonucleotides: The development of antisense therapeutics
38. Triple helix formation with purine-rich phosphorothioate-containing oligonucleotides covalently linked to an acridine derivative
39. Antileukemia effect of c-myc N3′→P5′ phosphoramidate antisense oligonucleotides in vivo
40. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation
41. Targeting c-myc in leukemia
42. Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene
43. DNA triplexes and regulation of the c-myc gene
44. DNA tetraplex formation in the control region of c-myc
45. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells
46. DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells
47. Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells
48. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells
49. Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes
50. Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices
51. Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins
52. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding
53. Effect of phosphorothioate modifications on the ability of GTn oligodeoxynucleotides to specifically recognize single-stranded DNA-binding proteins and to affect human cancer cellular growth
54. LMPCR for detection of oligonucleotide-directed triple helix formation: A cautionary note
55. Targeted gene knockout mediated by triple helix forming oligonucleotides
56. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target
57. c-Myc inactivation by mutant Max alters growth and morphology of NCI-H-630 colon cancer cells
58. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
59. Mechanisms of apoptosis by c-Myc
60. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide
61. Antisense oligonucleotides: Is the glass half full or half empty?
62. Progress in antisense oligonucleotide therapeutics